Onvansertib (PLK1 inhibitor) for CMML/MDS-MPN overlap
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-02-23 — Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms: Phase I trial (trial-early) underway evaluating onvansertib monotherapy for safety, optimal dosing, and preliminary efficacy in recurrent/refractory CMML and MDS/MPN overlap neoplasms — first-in-class PLK1 inhibition in this disease context. (novelty: 4)
Open questions
Related
Contributing findings
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
23-feb-2026
novelty 4
per-area 4
introduces